141 related articles for article (PubMed ID: 24791800)
1. [Preliminary analysis on the treatment of ventilator-associated pneumonia caused by pandrug-resistant Acinetobacter baumannii].
Wang LW; Zou L; Li HX; Li TZ
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2014 Apr; 36(2):185-8. PubMed ID: 24791800
[TBL] [Abstract][Full Text] [Related]
2. A retrospective analysis of carbapenem-resistant Acinetobacter baumannii-mediated nosocomial pneumonia and the in vitro therapeutic benefit of cefoperazone/sulbactam.
Xia J; Zhang D; Xu Y; Gong M; Zhou Y; Fang X
Int J Infect Dis; 2014 Jun; 23():90-3. PubMed ID: 24726664
[TBL] [Abstract][Full Text] [Related]
3. Risk factors of multidrug-resistant, extensively drug-resistant and pandrug-resistant Acinetobacter baumannii ventilator-associated pneumonia in a Medical Intensive Care Unit of University Hospital in Thailand.
Inchai J; Liwsrisakun C; Theerakittikul T; Chaiwarith R; Khositsakulchai W; Pothirat C
J Infect Chemother; 2015 Aug; 21(8):570-4. PubMed ID: 26026660
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the clinical efficacy between tigecycline plus extended-infusion imipenem and sulbactam plus imipenem against ventilator-associated pneumonia with pneumonic extensively drug-resistant Acinetobacter baumannii bacteremia, and correlation of clinical efficacy with in vitro synergy tests.
Jean SS; Hsieh TC; Hsu CW; Lee WS; Bai KJ; Lam C
J Microbiol Immunol Infect; 2016 Dec; 49(6):924-933. PubMed ID: 26341302
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the treatment efficacy between tigecycline plus high-dose cefoperazone-sulbactam and tigecycline monotherapy against ventilator-associated pneumonia caused by extensively drug-resistant Acinetobacter baumannii.
Qin Y; Zhang J; Wu L; Zhang D; Fu L; Xue X
Int J Clin Pharmacol Ther; 2018 Mar; 56(3):120-129. PubMed ID: 29319497
[TBL] [Abstract][Full Text] [Related]
6. Colistin-based treatment for extensively drug-resistant Acinetobacter baumannii pneumonia.
Khawcharoenporn T; Pruetpongpun N; Tiamsak P; Rutchanawech S; Mundy LM; Apisarnthanarak A
Int J Antimicrob Agents; 2014 Apr; 43(4):378-82. PubMed ID: 24613422
[TBL] [Abstract][Full Text] [Related]
7. Early experience with tigecycline for ventilator-associated pneumonia and bacteremia caused by multidrug-resistant Acinetobacter baumannii.
Schafer JJ; Goff DA; Stevenson KB; Mangino JE
Pharmacotherapy; 2007 Jul; 27(7):980-7. PubMed ID: 17594203
[TBL] [Abstract][Full Text] [Related]
8. [Cefoperazone-sulbactam plus minocycline in the treatment of extensively drug resistant Acinetobacter infections].
Shi Y; Xu YC; Liu Y; Du W; Rui X; Wang Y
Zhonghua Yi Xue Za Zhi; 2012 Oct; 92(40):2847-50. PubMed ID: 23290215
[TBL] [Abstract][Full Text] [Related]
9. Hospital-acquired pneumonia and ventilator-associated pneumonia in adults at Siriraj Hospital: etiology, clinical outcomes, and impact of antimicrobial resistance.
Werarak P; Kiratisin P; Thamlikitkul V
J Med Assoc Thai; 2010 Jan; 93 Suppl 1():S126-38. PubMed ID: 20364567
[TBL] [Abstract][Full Text] [Related]
10. Colistin alone or combined with sulbactam or carbapenem against A. baumannii in ventilator-associated pneumonia.
Yilmaz GR; Guven T; Guner R; Kocak Tufan Z; Izdes S; Tasyaran MA; Acikgoz ZC
J Infect Dev Ctries; 2015 May; 9(5):476-85. PubMed ID: 25989167
[TBL] [Abstract][Full Text] [Related]
11. [Efficacy of extended-infusion of carbapenem plus sulbactam for ventilator-associated pneumonia caused by extensive drug-resistant
Wang X; Hu Y; Que CL; Zhang H; Huang JJ; Cao J; Jin Z; Wang GF; Zhang W
Zhonghua Yi Xue Za Zhi; 2017 Oct; 97(38):2996-3000. PubMed ID: 29061006
[No Abstract] [Full Text] [Related]
12. Colistin and tigecycline susceptibility among multidrug-resistant Acinetobacter baumannii isolated from ventilator-associated pneumonia.
Dizbay M; Altuncekic A; Sezer BE; Ozdemir K; Arman D
Int J Antimicrob Agents; 2008 Jul; 32(1):29-32. PubMed ID: 18539006
[TBL] [Abstract][Full Text] [Related]
13. Treatment of Carbapenem-Resistant Acinetobacter baumannii Ventilator-Associated Pneumonia: Retrospective Comparison Between Intravenous Colistin and Intravenous Ampicillin-Sulbactam.
Zalts R; Neuberger A; Hussein K; Raz-Pasteur A; Geffen Y; Mashiach T; Finkelstein R
Am J Ther; 2016; 23(1):e78-85. PubMed ID: 24263165
[TBL] [Abstract][Full Text] [Related]
14. Use of adjunctive aerosolized antimicrobial therapy in the treatment of Pseudomonas aeruginosa and Acinetobacter baumannii ventilator-associated pneumonia.
Arnold HM; Sawyer AM; Kollef MH
Respir Care; 2012 Aug; 57(8):1226-33. PubMed ID: 22349038
[TBL] [Abstract][Full Text] [Related]
15. Ventilator-Associated Pneumonia due to Drug-Resistant
Čiginskienė A; Dambrauskienė A; Rello J; Adukauskienė D
Medicina (Kaunas); 2019 Feb; 55(2):. PubMed ID: 30781896
[No Abstract] [Full Text] [Related]
16. Clinical epidemiology, treatment and prognostic factors of extensively drug-resistant Acinetobacter baumannii ventilator-associated pneumonia in critically ill patients.
Tsioutis C; Kritsotakis EI; Karageorgos SA; Stratakou S; Psarologakis C; Kokkini S; Gikas A
Int J Antimicrob Agents; 2016 Nov; 48(5):492-497. PubMed ID: 27542315
[TBL] [Abstract][Full Text] [Related]
17. A combination regimen of meropenem, cefoperazone-sulbactam and minocycline for extensive burns with pan-drug resistant Acinetobacter baumannii infection.
Ning F; Shen Y; Chen X; Zhao X; Wang C; Rong Y; Du W; Wen C; Zhang G
Chin Med J (Engl); 2014; 127(6):1177-9. PubMed ID: 24622455
[No Abstract] [Full Text] [Related]
18. High-dose ampicillin-sulbactam as an alternative treatment of late-onset VAP from multidrug-resistant Acinetobacter baumannii.
Betrosian AP; Frantzeskaki F; Xanthaki A; Georgiadis G
Scand J Infect Dis; 2007; 39(1):38-43. PubMed ID: 17366011
[TBL] [Abstract][Full Text] [Related]
19. Antimicrobial treatment and clinical outcomes of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia.
Chan JD; Graves JA; Dellit TH
J Intensive Care Med; 2010; 25(6):343-8. PubMed ID: 20837632
[TBL] [Abstract][Full Text] [Related]
20. Acinetobacter baumannii ventilator-associated pneumonia: epidemiology, clinical characteristics, and prognosis factors.
Chaari A; Mnif B; Bahloul M; Mahjoubi F; Chtara K; Turki O; Gharbi N; Chelly H; Hammami A; Bouaziz M
Int J Infect Dis; 2013 Dec; 17(12):e1225-8. PubMed ID: 24094525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
